Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13821868 | 0.91 | CYP19A1 (0.59) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9913655 | 0.87 | CYP19A1 (0.51) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL1507825 | 0.78 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL8697493 | 0.77 | CYP19A1 (0.67) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8697636 | 0.77 | CYP19A1 (0.45) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL2348017 | 0.74 | CYP19A1 (0.61) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL1507734 | 0.73 | CYP19A1 (0.88) | CYP19A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL1507754 | 0.73 | CYP19A1 (0.88) | CYP19A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL1507798 | 0.72 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL1507987 | 0.72 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150524-B2 | Pure intermediate | GENERICS [UK] LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20130203826-A1 | Pure Intermediate | GENERICS [UK] LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| WO-2012025762-A2 | PURE INTERMEDIATE | GENERICS [UK] LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| EP-2212301-B1 | AN IMPROVED PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD (IN) | 2012-02-29 | — | — | EP | disclosed |
| US-8003804-B2 | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | CIPLA LIMITED (IN) | 2011-08-23 | — | — | US | disclosed |
| WO-2011000395-A1 | PURIFICATION OF LETROZOLE | SYNTHON B.V. (NL) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000395-A1 | PURIFICATION OF LETROZOLE | SYNTHON B.V. (NL) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000396-A1 | PURIFICATION OF LETROZOLE INTERMEDIATE | SYNTHON B.V. (NL) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000396-A1 | PURIFICATION OF LETROZOLE INTERMEDIATE | SYNTHON B.V. (NL) | 2011-01-06 | — | — | WO | disclosed |
| WO-2007054964-A2 | PROCESS FOR THE PREPARATION OF LETROZOLE | CADILA HEALTHCARE LIMITED (IN) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007039912-A1 | A ONE POT PROCESS FOR THE PREPARATION OF 4-[1-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | USV LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039912-A1 | A ONE POT PROCESS FOR THE PREPARATION OF 4-[1-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | USV LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
| US-20070066831-A1 | Process for the preparation of letrozole | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20060128775-A1 | Regiospecific process for the preparation of 4-[1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl) methyl] benzonitrile | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-06-15 | — | — | US | disclosed |
| EP-1594850-A2 | REGIOSPECIFIC PROCESS FOR THE PREPARATION OF 4- 1- (4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | Sun Pharmaceuticals Industries Ltd. (IN) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004076409-A2 | REGIOSPECIFIC PROCESS FOR THE PREPARATION OF 4-[1- (4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | CYP19A1, CYP2C19, CYP17A1 | CYP19A1 1/4885CYP3A4 4/4885CYP11B1 80/4885 |
| US-20070066831-A1 | Process for the preparation of letrozole | CYP19A1, CYP4B1, CYP3A4 | CYP19A1 1/4885CYP3A4 3/4885CYP11B1 14/4885 |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CYP19A1, HSD17B11, SHBG | CYP19A1 1/4885CYP3A4 6/4885CYP11B1 27/4885 |
| US-20130203826-A1 | Pure Intermediate | CYP19A1, CYP11A1, CYP11B1 | CYP19A1 1/4885CYP3A4 9/4885CYP11B1 3/4885 |
| US-20060128775-A1 | Regiospecific process for the preparation of 4-[1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl) methyl] benzonitrile | CYP4B1, KDM4B, CYP3A4 | CYP19A1 1741/4885CYP3A4 3/4885CYP11B1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.